Quarterly report · Q3
6323.TEDINET S100PY7W
Period2022-03-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥71.4bn | 2022-03-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥67.0bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥46.6bn | 2021-03-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥17.7bn | 2022-03-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥10.8bn | 2021-03-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥26.7bn | 2022-03-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.8bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.0bn | 2021-03-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥26.7bn | 2022-03-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥12.8bn | 2021-03-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥19.7bn | 2022-03-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.8bn | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.7bn | 2021-03-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.6bn | 2022-03-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥9.6bn | 2021-03-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥126.7bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥88.3bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥81.1bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥52.3bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥38.1bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥74.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥50.2bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥45.2bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥30.0bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.6bn | at 2022-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥1,138.05 | 2022-03-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥422.44 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥742.1 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥504.34 | 2021-03-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥186.14 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥1,135.91 | 2022-03-01 → 2022-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥740.72 | 2021-03-01 → 2022-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥503.42 | 2021-03-01 → 2021-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 54.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.4% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.0% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-11-30 | −¥14m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-11-30 | −¥14m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-11-30 | −¥495m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | segment profit | 2022-03-01 → 2022-11-30 | −¥116m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue | 2022-03-01 → 2022-11-30 | ¥71.1bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue external | 2022-03-01 → 2022-11-30 | ¥71.1bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥14m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | segment profit | 2022-03-01 → 2022-11-30 | ¥18.4bn |
| —segment total | revenue | 2022-03-01 → 2022-11-30 | ¥71.4bn |
| —segment total | revenue external | 2022-03-01 → 2022-11-30 | ¥71.4bn |
| —segment total | revenue intersegment | 2022-03-01 → 2022-11-30 | ¥14m |
| —segment total | segment profit | 2022-03-01 → 2022-11-30 | ¥18.2bn |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-11-30 | −¥17m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-11-30 | −¥17m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-11-30 | −¥309m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥395m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥395m |
| jpcrp040300-q3r_E02328-000Life Sciencereportable segment | segment profit | 2021-03-01 → 2021-11-30 | −¥42m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue | 2021-03-01 → 2021-11-30 | ¥46.2bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue external | 2021-03-01 → 2021-11-30 | ¥46.2bn |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥17m |
| jpcrp040300-q3r_E02328-000Semiconductor And Liquid Crystalreportable segment | segment profit | 2021-03-01 → 2021-11-30 | ¥11.1bn |
| —segment total | revenue | 2021-03-01 → 2021-11-30 | ¥46.6bn |
| —segment total | revenue external | 2021-03-01 → 2021-11-30 | ¥46.6bn |
| —segment total | revenue intersegment | 2021-03-01 → 2021-11-30 | ¥17m |
| —segment total | segment profit | 2021-03-01 → 2021-11-30 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 356
| Item | Context | Value | Unit |
|---|---|---|---|
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |